Serum Amyloid A Protein (SAA) in Colorectal Carcinoma
Authors:
- Ines GlojnarićIGInes Glojnarić
- Martin-Tino ČaslMČMartin-Tino Časl
- Diana ŠimićDŠDiana Šimić
- Josip LukačJLJosip Lukač
- 9 January 2001
- journal article
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 39 (2) , 129-33
Abstract
The changes in serum levels of serum amyloid A protein were studied in 67 patients suffering from colorectal carcinoma and compared to three other major acute phase proteins: C-reactive protein, alpha1-antichymotrypsin and alpha1-acid glycoprotein. Although the presence of colorectal carcinoma caused an increase in serum levels of all the acute phase reactants studied, serum amyloid A protein showed the most powerful reaction in pre-operative disease stage, with the mean value of 330 mg/l (range 7-2506 mg/l) as compared to the normal values of <1.2 mg/l obtained in 30 healthy adults. The mean serum amyloid A protein concentration increased to 487 mg/l after surgery, declining during the post-operative clinical course until the sixth chemotherapy cycle (from 167 mg/l to 64 mg/l), but never returned to the normal range. In the later chemotherapy cycles, mean serum amyloid A protein increased to 163 mg/l, probably as a result of the disease relapse. According to the statistical relations among exact confidence intervals for proportions, serum amyloid A protein showed the best specificity for colorectal carcinoma of all the acute phase proteins studied (83-100%) and also a sensitivity of 100%. We concluded that serum amyloid A protein seems to be a reliable parameter, which could be recommended for clinical routine as a non-specific tumour marker for colorectal carcinoma.Keywords
This publication has 28 references indexed in Scilit:
- Inflammation, the Acute Phase Response and AtherosclerosisClinical Chemistry and Laboratory Medicine (CCLM), 1999
- Serum Amyloid A (SAA): a Concise Review of Biology, Assay Methods and Clinical UsefulnessClinical Chemistry and Laboratory Medicine (CCLM), 1999
- C-Reactive Protein: Structural Biology and Host Defense FunctionClinical Chemistry and Laboratory Medicine (CCLM), 1999
- Acute phase proteins, C-reactive protein and serum amyloid A protein, as prognostic markers in the elderly inpatientAge and Ageing, 1997
- Human serum amyloid A (SAA) protein: a prominent acute‐phase reactant for clinical practiceEuropean Journal of Clinical Investigation, 1996
- Induction of acute phase proteins in mice and humans by treatment with AS101, an immunomodulator with radioprotective propertiesImmunopharmacology, 1995
- Acute phase proteins and recombinant IL-2 therapy: prediction of response and survival in patients with colorectal cancerClinical and Experimental Immunology, 1995
- The Value of Acute Phase Protein Measurements in Clinical PracticeAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 1992
- Properties of four acute phase proteins: C-reactive protein, serum amyloid a protein, α1-acid glycoprotein, and fibrinogenSeminars in Arthritis and Rheumatism, 1990
- Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis.Journal of Clinical Pathology, 1986